Skip to main content
International Journal of Preventive Medicine logoLink to International Journal of Preventive Medicine
. 2026 Sep 29;17:106. doi: 10.4103/ijpvm.ijpvm_401_25

Prevalence of Obstructive Sleep Apnea in the Adult Population of Saudi Arabia: A Systematic Review and Meta-analysis

Hasna Saleh Albalawi 1,✉, Abdulrahman Abdullah S Alelyani 1, Leen Omar Al Gelban 2, Latifah Abdullah N Alfaraj 3, Badr Mahmoud Ahmed 4, Dina Fahad Alshahrani 2, Abdulaziz A Alhumam 5, Abdullah Mohammed Aldakhil 6, Abdullah Abdulaziz Alsuwayyid 5, Lina Nasreldin Ahmed 7, Nada Ibrahim A Asiri 2, Hyder Osman Mirghani 1
PMCID: PMC13694049  PMID: 42921354

Abstract

Background:

Obstructive sleep apnea (OSA) is a common but often overlooked disorder with profound cardiometabolic and neurocognitive consequences. Various studies in Saudi Arabia have reported varying prevalence figures.

Objective:

To estimate the pooled prevalence of OSA among adults in Saudi Arabia.

Methods:

The systematic review and meta-analysis were carried out between May and August 2025 according to PRISMA 2020 guidelines. Observational studies that described the prevalence of OSA among adults (≥16 years) were considered. Pooled prevalence was computed using a random-effect model with Freeman–Tukey transformation. I2 statistics were used to determine the heterogeneity. Subgroup analysis was undertaken according to population, diagnostic tool, size of the sample, and region.

Results:

Thirty-three studies with 18,403 participants were included. The overall pooled prevalence of OSA was 26.96% (95% confidence interval [CI]: 20.98%–33.38%), with high heterogeneity (I2 = 98.9%). This significant heterogeneity is primarily attributed to variations in study populations (general vs. high-risk) and the diverse diagnostic criteria employed across the included studies. The prevalence was 15.95% (95% CI: 11.80%–20.60%) in the general population and 42.60% (95% CI: 29.47%–56.27%) in high-risk groups. The diagnostic method influenced estimates, with polysomnography (34.1%) and STOP-BANG (33.8%) yielding higher prevalence than the Berlin Questionnaire (28.5%). Regional variation was observed, with higher prevalence in Riyadh compared to Mecca.

Conclusions:

About one in four Saudi adults may have OSA, with prevalence markedly higher in high-risk groups. These findings underscore the need for national screening programs and targeted interventions to reduce the burden of undiagnosed OSA.

Keywords: Meta-analysis, OSA, prevalence, Saudi Arabia

Introduction

Obstructive sleep apnea (OSA) is a prevalent but frequently overlooked sleep-related breathing disorder, defined by recurrent collapse of the upper airway leading to intermittent hypoxia and sleep fragmentation.[1] Overnight polysomnography (PSG) is the gold standard diagnostic tool for OSA, quantifying the apnea–hypopnea index (AHI).[2] Based on the measured hourly AHI events, OSA is categorized into mild, moderate, and severe.[2] Other subjective validated screening tools are regularly used in clinical and epidemiological settings, for example., the STOP-BANG questionnaire, the Berlin Questionnaire (BQ), and the Epworth Sleepiness Scale (ESS).[3] Management of OSA ranges from weight reduction and lifestyle modifications to continuous positive airway pressure (CPAP), which is the first line of management for moderate to severe cases.[4] Other management also includes oral appliances, upper airway surgery, and more recently modalities such as hypoglossal nerve stimulation in select cases.[5]

Globally, OSA is estimated to affect 9% to 38% of the population.[6] Obesity, older age, male gender, and certain craniofacial anatomical features are all risk factors for the development of OSA.[7] Further lifestyle-related risk factors include smoking and alcohol consumption. Of particular importance is the link between OSA and cardiovascular and cardio-metabolic disorders such as hypertension, diabetes, and ischemic heart disease.[8] The sequelae of neglecting OSA encompass cognitive decline, poorer life quality, higher probability of stroke, arrhythmias, heart failure, and mortality.[8]

In Saudi Arabia, several studies have examined the prevalence of OSA in both community and high-risk populations.[9,10,11,12] However, the prevalence estimates tend to vary significantly. This variation may be explained by differences in study location, large versus smaller cities, and the year of recruitment, reflecting changes in diagnostic capacity, access to sleep laboratories, and general awareness of OSA over time. Taking into consideration that the country is dealing with an epidemic of obesity and cardiometabolic diseases, the burden of OSA is likely underestimated.[13,14] The current meta-analysis aims to pool the available figures of OSA in Saudi Arabia and investigate the sources of variation to define the scale of the problem and inform future healthcare planning and screening strategies.

Methods

This meta-analysis was conducted between May and August 2025 in accordance with the PRISMA 2020 guidelines, aiming to estimate the pooled prevalence of OSA among adults in Saudi Arabia.

Selection criteria

Selection criteria were guided by the Population, Exposure, Outcome framework, which is appropriate for prevalence meta-analyses. We included studies of adults aged ≥16 years living in Saudi Arabia (any nationality) and conducted in community, primary care, or hospital settings; this age threshold was selected because, within the Saudi healthcare system, patients aged 16 and older are typically managed in adult clinical settings rather than pediatric departments, making them relevant to an adult prevalence estimate. Eligible studies were observational and reported the prevalence of OSA diagnosed by PSG or a validated screening tool (e.g. STOP-Bang, BQ); there was no restriction on publication year. We excluded studies limited to children/adolescents (<16 years), studies conducted outside Saudi Arabia, and designs that do not provide prevalence data (case reports/series, editorials, reviews). We also excluded conference abstracts without full data, and any animal, or otherwise irrelevant studies.

Data sources and search strategy

Two authors independently searched PubMed/MEDLINE, Scopus, Web of Science Core Collection, Ovid, and Google Scholar. Searches were conducted with no date restriction and were limited to English language. We applied no filters for age, sex, or setting at the search stage. To keep the search consistent and avoid missed records, we used a predefined strategy that combined subject headings with free-text terms for OSA and Saudi Arabia (Supplementary Material). We exported all results to a reference manager, duplicates were removed, and reference lists of included papers and relevant reviews were screened to capture any additional studies.

Study selection and data extraction

Screening was conducted in Rayyan by two reviewers working independently. We imported all records from the database searches and screened titles and abstracts against the prespecified eligibility criteria. Any record judged eligible—or unclear—was taken to full-text review. Disagreements were settled by discussion; if unresolved, a third reviewer decided. Reasons for exclusion at the full-text stage were recorded, and the overall process is depicted in the PRISMA flow diagram.

Two reviewers independently extracted data into a predesigned Excel sheet. For each study, we recorded: first author and year, study design, study period, study population, region/city or care setting, gender, diagnostic, the OSA definition used, n with OSA or high risk, total assessed, prevalence (%), and any subgroup estimates reported. Entries were compared side-by-side, and any differences were resolved by discussion. Our primary endpoint was the pooled point prevalence of OSA among adults in Saudi Arabia.

Quality assessment

The methodological quality of the included studies was rated using the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.[15] It consists of 14 criteria, all of which assess potential sources of bias. Two investigators independently rated each study, and if any disagreement occurred, they discussed it mutually to reach a consensus. The quality of included studies was rated either good, fair, or poor, and this quality rating was taken into account when interpreting the pooled findings.

Statistical analysis

StatsDirect v4.0 (StatsDirect Ltd, Birkenhead, United Kingdom) was used for the analysis. Random-effects models using the DerSimonian-Laird method were employed as the primary analysis approach for pooled proportions with using the Freeman–Tukey double-arcsine as transformation to stabilize variance. We report pooled prevalence with 95% confidence intervals (CIs) and quantify heterogeneity with Cochran’s Q and I2. Publication bias was assessed with funnel plots; asymmetry was tested using Begg’s rank-correlation and Egger, with P < 0.05 considered significant. Sensitivity analyses were conducted in R – code in supplementary.

Results

Search results

The database search identified a total of 1424 records. After removing 756 duplicates, 84 records were marked as ineligible by automation tools, and 12 records were excluded for other reasons; 572 records remained for screening. Following title and abstract screening, 563 reports were sought for full-text retrieval. After a detailed assessment, 33 studies met the inclusion criteria and were included in the final review as shown in Figure 1.

Figure 1.

Figure 1

The PRISMA flowchart

Characteristics of included studies

A total of 33 studies comprising 18,403 participants were included.[9,10,11,12,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44] The included studies covered all major regions of Saudi Arabia, with the Western region (Jeddah, Mecca, Taif) most represented, followed by the Central region (Riyadh) and the Eastern Province (Dammam, Al-Ahsa). The Southern provinces and the Northern region contributed fewer studies. Sixteen studies assessed the general population (n = 13,320), 15 focused on high-risk groups (n = 4024; individuals with comorbidities such as obesity, diabetes, hypertension, cardiovascular disease, or metabolic syndrome), and two targeted student populations (n = 1059). Sample sizes ranged from 39 to 2682 participants. OSA was assessed using tools such as the BQ, STOP-BANG, and the ESS, while seven studies used PSG and one used home sleep apnea testing (HSAT) Case definitions varied, ranging from questionnaire cutoffs (e.g. BQ ≥2, STOP-BANG ≥3–5, ESS ≥11) to PSG-based criteria (AHI ≥5 events/hour; AHI ≥15 for moderate-to-severe OSA). A detailed summary of study characteristics is presented in Table 1.

Table 1.

An overview of the included studies

First author, year Study design Study population Region (city/area) or setting Gender Tool used OSA definition (e.g., AHI ≥5 or STOP-BANG ≥3) N with OSA or high risk Total
Wali S et al., 2015 Cross-sectional study Patients with CAD Jeddah, King Abdulaziz University Hospital Both STOP-BANG + PSG PSG AHI ≥5 88 156
Hakami A., 2023 Cross-sectional study General adult population Jazan Region Both Self-reported questionnaire Self-reported breathing symptoms (snoring/apnea) 90 670
Wali S et al., 2020 Cross-sectional study (2-stage) Patients with rheumatoid arthritis Jeddah, King Abdulaziz University Hospital Both Berlin Q + ESS + PSG AHI ≥5 (OSA), AHI ≥15 (moderate-severe) 61 105
AlAteeq et al., 2024 Cross-sectional study General adult population Riyadh, PHCs Both SLEEP-50 - 67 378
Goweda A et al., 2020 Cross-sectional study Medical Students Makkah, Umm Al-Qura University Both SLEEP-50 Total score ≥15 on items 1–8 + at least one item scored 3 or 4 72 438
Wali S., 2015 Cross-sectional study ESRD patients on hemodialysis Jeddah, 3 hospitals Both Berlin Q+ ESS + STOP-BANG BQ ≥2 157 355
AlTulaihi B et al., 2023 Cross-sectional study General adult population Riyadh, PHCs Both Berlin Q BQ ≥2 84 400
Ahmed A., 2019 Cross-sectional study General adult population Jeddah, FM clinic Both Berlin Q + ESS Combined measure was used 41 319
Alqurashi Y et al., 2024 Cross-sectional study Geriatric population Saudi Arabia community Both Athens Insomnia scale + STOP-BANG + SLUMS STOP-BANG score ≥3 259 343
Wali S et al., 2017 Cross-sectional study (2-stage) Saudi school employees Jeddah King Abdulaziz University Hospital. Both ESS+PSG AHI ≥5 based on PSG 236 2682
Wali S et al., 2023 Retrospective cohort study patients referred to sleep centers Jeddah, Saudi Arabia, at two sleep centers. Both PSG AHI ≥5 events/hour based on PSG 52 642
Alaa M. Alaqeel, 2025 Retrospective cohort study Morbidly obese-bariatric surgery unit Riyadh, Saudi Arabia (hospital - KAMC) Both PSG, ESS AHI ≥5 based on PSG 153 265
Al-Sebaei et al., 2023 Cross-sectional study General adult population Jeddah, Saudi Arabia, Dentistry clinic Both STOP-BANG STOP-BANG score ≥5 17 55
Al-Jewair et al., 2016 Cross-sectional study Adults dental patients Dammam, College of Dentistry Both Berlin Q + ESS BQ ≥2 46 200
Alanazi T et al., 2021 Cross-sectional study Adult asthmatic patients - pulmonary clinics Riyadh, Saudi Arabia (King Abdulaziz Medical City - KAMC) Both Berlin Q BQ ≥2 86 200
Alahmari M et al., 2019 Cross-sectional study male truck drivers Parking areas and gas stations on highways Male Berlin Q High risk of OSA 98 338
Alharbi SM et al., 2025 Cross-sectional study Medical students at King Saud University College of Medicine, King Saud University, Riyadh Both Berlin Q BQ ≥2 90 621
Alharthi MM et al., 2020 Cross-sectional study General adult population Taif city, Saudi Arabia Both Sleep apnea symptom index A mean score of ≥2 on the sleep apnea symptom index 18 756
Almeneessier et al., 2020 Case-control study (cross-sectional) Saudi pregnant women King Saud University Medical City, Riyadh Female Berlin Q Two or three categories of (BQ) 143 742
Alruwaili H et al., 2015 Cross-sectional study General adult population King Abdulaziz Medical City-Riyadh (KAMC-R), Riyadh Both Combination of BQ and ESS BQ ≥2, ESS ≥11 163 2095
Alsalamah et al., 2022 Cross-sectional study General adult population Saudi Arabia Both Modified STOP-BANG Moderate to severe OSA risk: Score 3-8 129 1377
Alsultan et al., 2022 Cross-sectional General adult population Al-Ahsa, Saudi Arabia Both (ESS) ESS score ≥11 97 360
Alhejaili, F. 2021 Cross-sectional Saudi airline pilots and first officers Jeddah – King Abdulaziz University Hospital Both Berlin Q, ESS, PSQI, FSS, PHQ-9, HSAT AHI ≥5 (HSAT) 27 39
Eltannir et al., 2019 Cross-sectional study General adult population Jeddah, PHCs Both STOP-BANG High risk of OSA: STOP-BANG Score 5-8 30 180
Alotaibi et al., 2021 Cross-sectional study Patients with glaucoma King Abdulaziz University Hospital (KAUH) in Jeddah Both STOP-BANG High risk of OSA: Yes to 5-8 questions 28 77
Shnaimer et al., 2022 Cross-sectional study Patients with type 2 diabetes Armed Forces Hospital in Jazan Both STOP-BANG STOP-BANG score ≥3 193 306
Wali et al., 2024 Observational study Saudi school employees school employees in Jeddah, Saudi Arabia Both PSG (AHI) score ≥5 235 2682
Kalakattawia et al., 2017 Cross-sectional study Patients with type 2 diabetes King Abdul-Aziz Specialist Hospital in Taif city Both STOP-BANG Severe risk: Score of 5-8 30 197
Alhejaili et al., 2024 Cross-sectional study Geriatric population Nursing homes in Jeddah Both Berlin Q BQ ≥2 108 153
Alyami YD et al., 2021 Cross-sectional study Dental patients Al-Farabi Dental College, Jeddah Both Berlin Q High risk 15 188
Al-Saqqaf R et al., 2017 Cross-sectional study Sickle Cell patients Hematology clinic, Jeddah Both Berlin Q High risk 13 106
Ahmed S. BaHammam, 2009 Cross-sectional study Female General adult population Primary health care clinics, Riyadh Female Berlin Q High-risk 156 400
Ahmed S. BaHammam, 2008 Cross-sectional study Male General adult population Primary health care clinics, Riyadh Male Berlin Q High-risk 192 578

OSA=Obstructive sleep apnea, AHI=Apnea–hypopnea index, ESS=Epworth Sleepiness Scale, BQ=Berlin Questionnaire, HSAT=Home sleep apnea testing, PSG=Polysomnography

Quality assessment

The methodological quality of the included studies was evaluated using the NIH Quality Assessment Tool for Cohort and Cross-sectional Studies. The majority of studies (29/33) were rated as fair quality, while the remaining were rated as good quality. No study was classified as poor. Overall, most studies fulfilled several key methodological domains. The detailed assessment of each domain for individual studies is presented in Supplementary Table 1.

Supplementary Table 1.

Quality assessment of cohort and cross-sectional studies

NIH quality assessment tool for Cohort Studies

Study ID Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Score Quality
Wali et al., 2015 Yes Yes Yes Yes No No No Yes Yes No Yes No Yes Yes 9 Fair
Hakami et al., 2023 Yes Yes No Yes Yes No No Yes Yes No Yes No NA No 7 Fair
Wali et al., 2020 Yes Yes Yes Yes No No Yes Yes Yes No Yes NR Yes Yes 10 Good
AlAteeq et al., 2024 Yes Yes CD Yes Yes No No Yes Yes No Yes No NA No 7 Fair
Goweda et al., 2020 Yes Yes No Yes No No Yes Yes Yes No Yes No NA No 7 Fair
Wali et al., 2015 Yes Yes Yes Yes No No Yes Yes Yes No Yes No NA Yes 9 Fair
AlTulaihi et al., 2023 Yes Yes NR Yes Yes No No Yes Yes No Yes No Yes Yes 9 Fair
Ahmed et al., 2019 Yes Yes Yes Yes No No No Yes Yes No Yes NR Yes Yes 9 Fair
Alqurashi et al., 2024 Yes Yes NR Yes No No No Yes Yes No Yes No NA Yes 7 Fair
Wali et al., 2017 Yes Yes Yes Yes No No No Yes Yes No Yes Yes Yes Yes 10 Good
Wali et al., 2023 Yes Yes NR Yes No No No Yes Yes No Yes Yes NA Yes 8 Fair
Alaqeel et al., 2025 yes Yes CD Yes No Yes Yes Yes Yes No Yes NR Yes Yes 10 Good
Al-Sebaei et al., 2023 Yes Yes CD Yes No No No Yes Yes No Yes NR Yes Yes 8 Fair
Al-Jewair et al., 2016 Yes Yes Yes Yes Yes No No Yes Yes No Yes NR Yes Yes 10 Good
Alanazi et al., 2021 Yes Yes Yes Yes No No No Yes Yes No Yes NR Yes Yes 9 Fair
Alahmari et al., 2019 Yes Yes NR Yes No No CD Yes Yes No Yes NR Yes Yes 8 Fair
Alharbi et al., 2025 Yes Yes Yes Yes Yes No No Yes Yes No Yes No NA Yes 9 Fair
Alharthi et al., 2020 Yes Yes CD Yes No No No Yes Yes No Yes No NA Yes 7 Fair
Almeneessier et al., 2020 Yes Yes NR Yes Yes No No Yes Yes No Yes No NA Yes 8 Fair
Alruwaili et al., 2015 Yes Yes Yes Yes No No No Yes Yes No Yes No Yes Yes 9 Fair
Alsalamah et al., 2022 Yes Yes NR Yes Yes No No Yes Yes No Yes No NA Yes 8 Fair
Alsultan et al., 2022 Yes Yes Yes Yes Yes No No Yes Yes No Yes No NA Yes 9 Fair
Alhejaili et al., 2021 Yes Yes Yes Yes No No No Yes Yes No Yes Yes NA Yes 9 Fair
Eltannir et al., 2019 Yes Yes NR Yes Yes No No Yes Yes No Yes No NA Yes 8 Fair
Alotaibi et al., 2021 Yes Yes No Yes No No No Yes Yes No Yes No NA No 6 Fair
Shnaimer et al., 2022 Yes Yes Yes Yes Yes No No Yes Yes No Yes No NA Yes 9 Fair
Wali et al., 2024 Yes Yes No Yes No No No Yes Yes No Yes No NA Yes 7 Fair
Kalakattawia et al., 2017 Yes Yes Yes Yes No No No Yes Yes No Yes No NA No 7 Fair
Alhejaili et al., 2024 Yes Yes CD Yes No No No Yes Yes No Yes No NA Yes 7 Fair
Alyami et al., 2021 Yes Yes Yes Yes No No No Yes Yes No Yes NR Yes Yes 9 Fair
Al-Saqqaf et al., 2017 Yes Yes NR Yes No No NA Yes Yes No Yes NR NA Yes 7 Fair
BaHammam et al., 2009 Yes Yes Yes Yes Yes No No Yes Yes No Yes NR Yes No 9 Fair
BaHammam et al., 2008 Yes Yes Yes Yes No No No Yes Yes No Yes NR Yes No 8 Fair

Overall pooled prevalence of obstructive sleep apnea

The meta-analysis of 33 studies including 18,403 participants demonstrated a pooled prevalence of OSA of 26.96% (95% CI: 20.98%–33.38%; 95% prediction interval: 1.91%–66.03%) using a random-effects model (DerSimonian–Laird), as illustrated in the forest plot Figure 2. Heterogeneity statistics were: (Cochran’s Q = 2,796.98, df = 32, P < 0.0001; I2 = 98.9%, 95% CI: 98.8%–98.9%).

Figure 2.

Figure 2

A forest plot of all included studies of obstructive sleep apnea prevalence in Saudi Arabia

The funnel plot for publication bias is shown in Figure 3. Begg–Mazumdar’s test: τ = 0.458, P = 0.0001; Egger’s regression: bias = 11.28, 95% CI: 7.85–14.71, P < 0.0001; Harbord’s test: bias = 14.38, 95% CI. CI: 8.71–20.04, P < 0.0001.

Figure 3.

Figure 3

A funnel plot of all included studies of obstructive sleep apnea prevalence in Saudi Arabia

Subgroup analysis

In the general population (16 studies; n = 13320), the pooled prevalence of OSA was 15.95% (95% CI: 11.80%–20.60%; 95% prediction interval: 3.08%–35.83%) under a random-effects model, with heterogeneity of (I2 = 97.8%, Cochran’s Q = 670.95, df = 15, P < 0.0001), as shown in Figure 4. Evidence of publication bias was detected, supported by Begg–Mazumdar’s test (τ = 0.483, P = 0.0086), Egger’s regression (bias = 7.79, P = 0.0008), and Harbord’s test (bias = 9.55, P = 0.0165).

Figure 4.

Figure 4

Forest plot of pooled obstructive sleep apnea prevalence in the general population

In contrast, among high-risk populations (15 studies; n = 4320), the pooled prevalence was markedly higher at 42.60% (95% CI: 29.47%–56.27%; 95% prediction interval: 2.64–90.37%), with high heterogeneity (I2 = 98.7%, Cochran’s Q = 1041.34, df = 14, P < 0.0001) [Figure 5]. Publication bias results were mixed: Egger’s test indicated small-study effects (bias = 13.30, P = 0.0072), whereas Begg–Mazumdar (τ = 0.20, P = 0.3282) and Harbord’s test (P = 0.1099) did not show significant bias.

Figure 5.

Figure 5

Forest plot of pooled obstructive sleep apnea prevalence in high-risk populations

Subgroup analysis according to the diagnostic tool showed a pooled OSA prevalence of 33.8% (95% CI: 11.9%–60.0%; I2 = 99.3%) across seven studies using the STOP-BANG questionnaire, 34.1% (95% CI: 20.8–48.8%; I2 = 99.1%) across seven studies using PSG, and 28.5% (95% CI: 20.7%–37.1%; I2 = 97.2%) across 12 studies using the BQ, as shown in Figure 6, which was lower than the STOP-BANG and PSG estimates. In the sample-size subgroup analysis, studies with <300 participants (k = 13) showed a pooled prevalence of 36.6% (95% CI: 24.3%–50.0%) with high heterogeneity (I2 = 97.1%), whereas studies with ≥300 participants (k = 20) showed a pooled prevalence of 21.5% (95% CI: 15.3%–28.3%) with even higher heterogeneity (I2 = 99.0%). In the regional subgroup analysis, studies conducted in the Riyadh region (k = 9) reported a pooled prevalence of 26.8% (95% CI: 16.8%–38.1%), while those from the Mecca region (k = 20) reported a pooled prevalence of 22.0% (95% CI: 15.8%–29.0%) [Figure 6].

Figure 6.

Figure 6

Subgroup analysis of the pooled prevalence of obstructive sleep apnea in Saudi Arabia according to diagnostic tool, sample size, and study region

Sensitivity analysis

Leave-one-out sensitivity analysis was performed to assess the influence of individual studies on the pooled prevalence [Figure 7]. Excluding any single study produced only minor changes in the overall estimate. The baseline pooled prevalence was 27.0% (95% CI: 21.0%–33.4%). The largest downward shift occurred when Alqurashi et al. (2024) were omitted, reducing the pooled prevalence to 25.5% (−1.5% points). The largest upward shift was observed after excluding Alharthi et al. (2020), which increased the pooled prevalence to 28.1% (+1.1% points; +4.1% relative change). For all other studies, the pooled prevalence remained within 26%–28%, The lowest heterogeneity observed was 98.6% and the highest was 98.9%, and no single study exerted a disproportionate influence. These findings indicate that the overall estimate is robust despite high heterogeneity.

Figure 7.

Figure 7

Leave-one-out sensitivity analysis of pooled obstructive sleep apnea prevalence

Meta-regression analysis

To explore sources of the substantial heterogeneity (I2 = 98.9%), we conducted univariable random-effects meta-regression analyses. Study population was a significant moderator (P < 0.0001), with high-risk populations showing prevalence 29.7% points higher than general populations (coefficient = 0.297, 95% CI: 0.184–0.410), explaining 36.1% of between-study variance. Sample size was also significantly associated with prevalence (coefficient = −0.0002 per participant, P = 0.0001), with larger studies reporting lower estimates and accounting for 28.2% of heterogeneity. In contrast, diagnostic method showed no significant association (P = 0.246, R2 = 0%), and publication year showed no temporal trend (P = 0.794, R2 = 0%). Despite these findings, substantial residual heterogeneity persisted in all models (I2 residual >98%), indicating that population type and sample size, while significant moderators, do not fully explain the observed variability.

Discussion

This meta-analysis, pooling data from more than 18,000 participants across 33 studies in Saudi Arabia, found a pooled prevalence of OSA of 26.9%. Among high-risk individuals, the pooled prevalence exceeded 40%. Comparatively, in general population-based samples, the average was closer to 16%. The results of this analysis indicate that OSA is one of the most pressing health concerns in Saudi Arabia, although it is not sufficiently recognized, and the risk is heightened due to particular epidemiological factors, lifestyle, and health care system challenges.

The pooled prevalence of OSA in Saudi Arabia appears to be among the highest figures in the world, comparable to Western nations. For instance, a recent meta-analysis from China, based on 62 studies with more than 178,000 participants, reported a pooled prevalence of 11.8%, although rates rose significantly over time, reaching 26.9% in surveys conducted between 2021 and 2024.[45] Other population-based estimates from the United States suggest that about 30% of the population have OSA.[46] Estimates from Europe suggest that nearly 44% of adults may have OSA when applying AASM 2012 criteria, with around 23% meeting criteria for moderate to severe disease.[47]

Pooled estimates in Saudi Arabia were notably marked by significant heterogeneity that could not be resolved by subgrouping or sensitivity analysis. This persistent heterogeneity can be attributed to several factors. The first is the considerable diversity in study populations. For instance, studies of the general population varied in their settings and age distributions, which likely contributed to inconsistent prevalence estimates. In addition, studies conducted in high-risk groups differed considerably in the conditions used to define risk. Some investigations focused on specific clinical populations, such as patients with coronary artery disease in Jeddah,[36] individuals with rheumatoid arthritis attending tertiary hospitals,[38] patients with end-stage renal disease undergoing hemodialysis,[10] morbidly obese patients,[11] diabetic patients,[34,35] or geriatric cases,[27] each naturally exhibiting variable risk of OSA. Other studies targeted distinct groups such as university students in Riyadh and Makkah, pregnant women, or occupational cohorts including truck drivers and airline pilots, each with unique risk profiles compared to the general population. In contrast, studies that sampled the general adult population, such as those from Riyadh primary health centers and the Jazan region, tended to report lower prevalence.[20,33,42,43] Similarly, some studies came from clinical settings, for example, dental clinics or pulmonary clinics, where the prevalence of OSA is inherently higher because of other health issues.[17,20] These variations highlight the profound influence of sample selection on the estimation of OSA burden.

Diagnostic methodology emerged as a key driver of observed heterogeneity. The contrasting performance characteristics of screening tools substantially affected prevalence estimates. STOP-BANG, designed with high sensitivity to prioritize case detection, systematically overestimates OSA prevalence (pooled estimate: 33.8% across 7 studies). Conversely, the BQ, with lower sensitivity but higher specificity, systematically underestimates prevalence (pooled estimate: 28.5% across 12 studies). This 5.3%-point difference reflects the inherent psychometric trade-offs between these instruments. The intermediate position of PSG-based estimates (34.1% across 7 studies) suggests STOP-BANG may more closely approximate true prevalence in screening contexts. This systematic variation in screening tool performance represents a critical methodological driver of the wide range of prevalence estimates observed. Nonetheless, substantial heterogeneity persisted even within each diagnostic subgroup (I2 >97% for all), indicating that population characteristics, study settings, and implementation protocols also contribute significantly to variability. The wide 95% prediction intervals (overall: 1.91%–66.03%; general population: 3.08%–35.83%; high-risk: 2.64%–90.37%) reflect the substantial heterogeneity and indicate that in future studies conducted in similar Saudi Arabian populations, the observed OSA prevalence could vary considerably depending on the specific population, setting, and diagnostic approach. This emphasizes the importance of context-specific prevalence estimates and highlights the need for standardized diagnostic criteria and reporting in epidemiological studies of OSA.

Our meta-analysis detected significant publication bias (Begg–Mazumdar, Egger, and Harbord tests, all P < 0.01), with positive bias coefficients indicating overrepresentation of smaller studies reporting higher prevalence estimates. This suggests that our pooled prevalence of 26.96% may overestimate the true population prevalence. Publication bias was more pronounced in the general population subgroup than in high-risk populations. Despite this limitation, the large number of studies (n = 33) and participants (n = 18,403), the consistency of findings across diagnostic methods, and robust sensitivity analyses support the conclusion that OSA prevalence in Saudi Arabia is substantial. Our estimate should be interpreted as likely representing an upper bound of the true prevalence.

Another essential note is that most of the studies included came from the Western and Central regions, Jeddah, Riyadh, and Makkah, while the Southern and Northern regions were scarcely represented. The differences in sleep lifestyle, healthcare, obesity, and change of sleep disorder awareness from one region to another probably cause the variation. Another factor that could have influenced the results would have been the timeframe of the included studies. Older studies tended to report lower figures, probably because of low awareness and the lack of proper screening and diagnostic tools for OSA at that time.[48] The more recent studies reported higher rates, partially due to increased levels of awareness and enhanced screening and diagnostic practices. These temporal trends parallel the rising prevalence of obesity and diabetes in the Kingdom, which further exacerbates the burden of OSA.[49]

Left untreated, OSA poses a greater risk to hypertension, diabetes, stroke, arrhythmias, and cardiovascular death, all of which are abundantly well known in Saudi Arabia.[8] It also poses a risk to greater cognitive impairment, lesser work productivity, and greater road traffic accidents, an especially grave concern in a nation with one of the worst statistics for traffic accidents.[19] While hospitals are scaling up, diagnostic infrastructure remains lacking. There are still too few accredited sleep centers and trained specialists to meet demand. This indicates that the burden outweighs capacity and implies that a large number of OSA cases go undiagnosed or untreated at a needless health and economic cost.

To effectively reduce the burden of OSA in Saudi Arabia, attention must then be directed to primary prevention by managing modifiable risk factors, awareness, and long-term management. Public health campaigns should intensify their efforts toward lifestyle changes, focusing on obesity as the most important factor associated with OSA.[50] On the clinical side, there should be a much stronger emphasis on giving patients timely access to suitable diagnostic tools, such as PSG, and addressing issues surrounding treatment adherence, particularly for CPAP. Increasing knowledge among both physicians and the population will ensure earlier identification and management of the disorder.

Future research should go beyond mere prevalence estimation to track longitudinal changes over time and thus evaluate the effects of lifestyle changes and policy-based interventions. Genetic, cultural, and lifestyle factors unique to the Saudi population would also be worthy considerations in understanding disease determinants. Besides, future research on treatment adherence and patient-reported outcomes will enhance understanding of the real-world effectiveness of management strategies.

Strengths and limitations

This study has some strengths, including a comprehensive search strategy, inclusion of diverse populations and regions, and the first pooled national estimate of OSA prevalence in Saudi Arabia. Nonetheless, several limitations must be acknowledged. The extreme heterogeneity reduces precision and necessitates cautious interpretation. Future studies should explore different subgroups and meta-regression analyses. The predominance of questionnaire-based diagnosis introduces risk of misclassification. Additionally, one study (Hakami 2023) relied on self-reported breathing symptoms (habitual snoring and witnessed apneas) rather than a validated screening instrument, which may have introduced measurement bias; however, sensitivity analysis excluding this study showed minimal impact on the pooled prevalence estimate (change <1%) and did not materially alter our conclusions. Underrepresentation of certain regions limits generalizability. Evidence of publication bias also suggests possible overestimation. Furthermore, the cross-sectional design of nearly all included studies precludes inference on incidence, temporal trends, or the impact of interventions.

Conclusions

This meta-analysis demonstrates that OSA affects approximately one in four adults in Saudi Arabia (26.96%), with prevalence exceeding 40% among high-risk populations. This substantial burden necessitates urgent action. We recommend: implementing standardized screening protocols (STOP-BANG or BQ) in primary care settings, targeting high-risk groups with diabetes, hypertension, and obesity; expanding accredited sleep diagnostic centers and specialist training, particularly in underserved regions; developing national awareness campaigns for both healthcare providers and the public; establishing evidence-based clinical practice guidelines tailored to the Saudi population; and conducting future research with standardized methods to investigate regional variations, genetic factors, and intervention effectiveness. These actionable recommendations provide a framework for reducing the burden of undiagnosed OSA and improving health outcomes in Saudi Arabia.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.

References

  • 1.Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: A review. JAMA. 2020;323:1389. doi: 10.1001/jama.2020.3514. [DOI] [PubMed] [Google Scholar]
  • 2.Laratta CR, Ayas NT, Povitz M, Pendharkar SR. Diagnosis and treatment of obstructive sleep apnea in adults. CMAJ. 2017;189:E1481–8. doi: 10.1503/cmaj.170296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chen R, Zhang Y, Ye W, Chen Z, Liao W, Liao H, Sun T, et al. Improving OSA screening efficiency with subjective questionnaires: Integrating STOP-Bang, ESS, and Berlin. Front Med. 2025;12:1581904. doi: 10.3389/fmed.2025.1581904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ellender CM, Vakulin A, Stocks N, Chai-Coetzer CL. Management of obstructive sleep apnoea in primary care. Aust J Gen Pract. 2024;53:363–9. doi: 10.31128/AJGP-08-23-6933. [DOI] [PubMed] [Google Scholar]
  • 5.Nag DS, Chatterjee A, Patel R, Sen B, Pal BD, Wadhwa G. Recent advances in the management of obstructive sleep apnea. World J Clin Cases. 2024;12:5456–61. doi: 10.12998/wjcc.v12.i24.5456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Iannella G, Pace A, Bellizzi MG, Magliulo G, Greco A, De Virgilio A, et al. The Global Burden of Obstructive Sleep Apnea. Diagnostics (Basel) 2025;15:1088. doi: 10.3390/diagnostics15091088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Yayan J, Rasche K. A systematic review of risk factors for sleep apnea. Prev Med Rep. 2024;42:102750. doi: 10.1016/j.pmedr.2024.102750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tasali E, Pamidi S, Covassin N, Somers VK. Obstructive sleep apnea and cardiometabolic disease: Obesity, hypertension, and diabetes. Circ Res. 2025;137:764–87. doi: 10.1161/CIRCRESAHA.125.325676. [DOI] [PubMed] [Google Scholar]
  • 9.Wali S, Kanbr O, Alhejaili F, Alshumrani R, Manzar MD, Mansour H. Prevalence and characteristics of positional obstructive sleep apnea in a Saudi population-based cohort. Medicine (Baltimore) 2024;103:e40455. doi: 10.1097/MD.0000000000040455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wali SO, Alkhouli A, Howladar M, Ahmad I, Alshohaib S, Al-Ghamdi S, Krayem A. Risk of obstructive sleep apnea among Saudis with chronic renal failure on hemodialysis. Ann Thorac Med. 2015;10:263–8. doi: 10.4103/1817-1737.164300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Alaqeel AM, Aldammas MA, Alaraik EF, Abanumay FM, Aleissi SA, Nashwan SZ, et al. The prevalence and predictors of obstructive sleep apnea in patients undergoing bariatric surgery in Saudi Arabia. Saudi Med J. 2025;46:274–81. doi: 10.15537/smj.2025.46.3.20240851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Alhejaili F, Kanbr O, Jastaniah N, Ismail R, Qalai T, Alotaibi R, et al. Sleep disorders among elderly in Saudi Arabia: A cross-sectional study. Ann Thorac Med. 2024;19:251–7. doi: 10.4103/atm.atm_57_24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Salem V, AlHusseini N, Abdul Razack HI, Naoum A, Sims OT, Alqahtani SA. Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review. Obes Rev. 2022;23:e13448. doi: 10.1111/obr.13448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tash AA, Al-Bawardy RF. Cardiovascular disease in Saudi Arabia: Facts and the way forward. J Saudi Heart Assoc. 2023;35:148–62. doi: 10.37616/2212-5043.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Study Quality Assessment Tools. NHLBI, NIH. [[Last cited on 2025 Sept 05]]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools .
  • 16.Ahmad AN, McLeod G, Al Zahrani N, Al Zahrani H. Screening for high risk of sleep apnea in an ambulatory care Setting in Saudi Arabia. Int J Environ Res Public Health. 2019;16:459. doi: 10.3390/ijerph16030459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Al-Jewair TS, Nazir MA, Al-Masoud NN, Alqahtani ND. Prevalence and risks of habitual snoring and obstructive sleep apnea symptoms in adult dental patients. Saudi Med J. 2016;37:183–90. doi: 10.15537/smj.2016.2.12852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Al-Sebaei MO, Bamashmous MS, Mirdad MH, Sindi MA. Prevalence of patients at risk for developing obstructive sleep apnea based on the STOP-BANG questionnaire at King Abdulaziz University Faculty of Dentistry. Clin Exp Dent Res. 2023;9:198–203. doi: 10.1002/cre2.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Alahmari MD, Alanazi TM, Batawi AA, Al-Osaimi EA, Alrabeeah S, Jebakumar Z, et al. Sleepy driving and risk of obstructive sleep apnea among truck drivers in Saudi Arabia. Traffic Inj Prev. 2019;20:498–503. doi: 10.1080/15389588.2019.1608975. [DOI] [PubMed] [Google Scholar]
  • 20.Alanazi TM, Alghamdi HS, Alberreet MS, Alkewaibeen AM, Alkhalefah AM, Omair A, et al. The prevalence of sleep disturbance among asthmatic patients in a tertiary care center. Sci Rep. 2021;11:2457. doi: 10.1038/s41598-020-79697-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.AlAteeq MA, Alghaihab MM, Marghlani LK, Shamsaddin LA, Alghamdi RK, Alfadley MA. Comparing the prevalence of sleep disorders among underweight, normal, overweight, and obese adults in Riyadh, Saudi Arabia. Cureus. 2024;16:e58858. doi: 10.7759/cureus.58858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Alharbi SM, Alanazi AA, Alamri AS, Alaluan HF, Alhuways WA, Suwayid RK, et al. Obstructive sleep apnea: Prevalence, Risk factors, and impact on the academic performance of medical students at a Saudi Arabian University. Saudi J Med Med Sci. 2025;13:61–7. doi: 10.4103/sjmms.sjmms_5_24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Alharthi MM, Altowairqi MH, Alamri SS, Mashrah HT, Almalki MA, Aljuaid EF. Risk assessment of obstructive sleep apnea among gastroesophageal reflux disease patients in Taif, Saudi Arabia. J Family Med Prim Care. 2020;9:1633–9. doi: 10.4103/jfmpc.jfmpc_882_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Alhejaili F, Hafez A, Wali S, Alshumrani R, Alzehairi AM, Balkhyour M, et al. Prevalence of obstructive sleep apnea among Saudi Pilots. Nat Sci Sleep. 2021;13:537–45. doi: 10.2147/NSS.S299382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Almeneessier AS, Alangari M, Aldubayan A, Alsharidah A, Altaki A, Olaish AH, et al. Prevalence of symptoms and risk of obstructive sleep apnea in Saudi pregnant women. Ann Thorac Med. 2020;15:163–70. doi: 10.4103/atm.ATM_59_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Alotaibi M, Alsubaie M, Alharthi A, Alnabri A, Bormah A, Alafif K, Alhibshi N. The risk of obstructive sleep apnea in open-angle glaucoma patients. Cureus. 2021;13:e18699. doi: 10.7759/cureus.18699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Alqurashi YD, AlHarkan K, Aldhawyan A, Bahamdan A, Aldulijan FA, Alsamin SI, et al. Risk of obstructive sleep apnea and its relation to cognitive functions among Saudi Older Adults. Med Arch. 2024;78:51–4. doi: 10.5455/medarh.2024.78.51-54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Alruwaili H, Ahmed A, Fatani A, Al-Otaibi K, Al-Jahdali S, Ali Y, et al. Symptoms and risk for obstructive sleep apnea among sample of Saudi Arabian adults. Sleep Biol Rhythms. 2015;13:332–41. [Google Scholar]
  • 29.Alsalamah IM, Abusaris R. Prevalence and associated factors of obstructive sleep apnea in Saudi Arabia: A web based questionnaire based study. Global J Health Sci. 2022;14:61–8. [Google Scholar]
  • 30.Alsultan A, Al Sahlawi M, Agha M. Prevalence of obstructive sleep apnea symptoms among the adult population in Al-Ahsa, Saudi Arabia. Cureus. 2022;14:e31082. doi: 10.7759/cureus.31082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.AlTulaihi B, Alassafi MT, Alanazi FH, Ban Owaiwid LN, Alasmari H, Alhaddab MM, et al. Symptoms and risk of obstructive sleep apnea in patients attending primary health care clinics in Riyadh, Saudi Arabia. Cureus. 2023;15:e33543. doi: 10.7759/cureus.33543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zakaria Eltannir A, Hassan A, Awad Alradadi S. Prevalence and determinant of obstructive sleep apnea in patients attending primary health care centers in ministry of health and international medical center in Jeddah, 2018. J Prev Med Holist Health. 2019;5:13–9. [Google Scholar]
  • 33.Hakami A, Hakami RA, Al-Amer MA, Sharahili LM, Zuqayl AH, Hakami TK, et al. Prevalence of sleep disorders among the general population of the Jazan Region of Southwest Saudi Arabia. Cureus. 2023;15:e46218. doi: 10.7759/cureus.46218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kalakattawi RM, Kalakattawi AM, Alsuqati FA, Alzhrani SA, Alhamyani AH, Alhamyani AH, et al. Risk of obstructive sleep apnea assessment among patients with type 2 diabetes in Taif, Saudi Arabia. J Clin Med Res. 2017;9:1002–6. doi: 10.14740/jocmr3189w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Shnaimer JA, Dahlan HM, Hanbashi FM, Bahammam AS, Gosadi IM. Assessment of the risk of obstructive sleep apnoea among patients with type 2 diabetes and its associated factors using the STOP-BANG questionnaire: A cross-sectional study. J Taibah Univ Med Sci. 2022;17:606–13. doi: 10.1016/j.jtumed.2021.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wali SO, Alsharif MA, Albanji MH, Baabbad MS, Almotary HM, Alama N, et al. Prevalence of obstructive sleep apnea among patients with coronary artery disease in Saudi Arabia. J Saudi Heart Assoc. 2015;27:227–33. doi: 10.1016/j.jsha.2015.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Wali SO, Abalkhail B, Krayem A. Prevalence and risk factors of obstructive sleep apnea syndrome in a Saudi Arabian population. Ann Thorac Med. 2017;12:88–94. doi: 10.4103/1817-1737.203746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wali S, Mustafa M, Manzar D, Bawazir Y, Attar S, Fathaldin O, et al. Prevalence of obstructive sleep apnea in patients with rheumatoid arthritis. J Clin Sleep Med. 2020;16:259–65. doi: 10.5664/jcsm.8178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wali SO, AlQassas I, Qanash S, Mufti H, Alamoudi M, Alnowaiser M, et al. The Prevalence of positional obstructive sleep apnea in a sample of the Saudi population. J Epidemiol Glob Health. 2023;13:129–39. doi: 10.1007/s44197-023-00089-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Abdelmoaty Goweda R, Hassan-Hussein A, Ali Alqahtani M, Janaini MM, Alzahrani AH, et al. Prevalence of sleep disorders among medical students of Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia. J Public Health Res. 2020;9((Suppl 1)):2020. doi: 10.4081/jphr.2020.1921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Alyami YD, Sabeh AM, Bin Afif AA, Yousef Roblah YM, Abdul Rahman DI, Alfarsi MK, et al. Prevalence and risk of obstructive sleep apnea and association with orofacial symptoms in patients attending the dental clinics. J Pharm Bioallied Sci. 2021;13((Suppl 1)):S571–4. doi: 10.4103/jpbs.JPBS_537_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Bahammam AS, Al-Rajeh MS, Al-Ibrahim FS, Arafah MA, Sharif MM. Prevalence of symptoms and risk of sleep apnea in middle-aged Saudi women in primary care. Saudi Med J. 2009;30:1572–6. [PubMed] [Google Scholar]
  • 43.BaHammam AS, Alrajeh MS, Al-Jahdali HH, BinSaeed AA. Prevalence of symptoms and risk of sleep apnea in middle-aged Saudi males in primary care. Saudi Med J. 2008;29:423–6. [PubMed] [Google Scholar]
  • 44.Al-Saqqaf R, Merdad R, Wali S, Al-Sayes F, Mukharesh L, Batawi S, et al. The prevalence of obstructive sleep apnea in adult patients with sickle cell disease. J Appl Hematol. 2017;8:16. [Google Scholar]
  • 45.Niu Y, Sun S, Wang Y, Chen L, Shao Y, Zhang X. Spatiotemporal Trends in the prevalence of obstructive sleep apnea across China: A multilevel meta-analysis incorporating geographic and demographic stratification (2000-2024) Nat Sci Sleep. 2025;17:879–903. doi: 10.2147/NSS.S525547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Sönmez I, Dupuy AV, Yu K, Cronin J, Yee J, Azarbarzin A. 0635 Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States. Sleep. 2025;48((Supplement_1)):A277–8. doi: 10.1016/j.rmed.2025.108348. [DOI] [PubMed] [Google Scholar]
  • 47.Malhotra A, Heinzer R, Morrell MJ, Penzel T, Pepin JL, Valentine K, et al. Late breaking abstract-European prevalence of OSA in adults: Estimation using currently available data. Sleep and control of breathing. European Respiratory Society. 2018. [[Last cited o 2025 Sept 05]]. p. p. OA4961. Available from: https://publications.ersnet.org/lookup/doi/10.1183/13993003.congress-2018.OA4961 .
  • 48.BaHammam A. Sleep medicine in Saudi Arabia: Current problems and future challenges. Ann Thorac Med. 2011;6:3. doi: 10.4103/1817-1737.74269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Almubark RA, Alqahtani SA. Epidemiology of obesity and control interventions in Saudi Arabia. East Mediterr Health J. 2023;29:987–94. doi: 10.26719/emhj.23.086. [DOI] [PubMed] [Google Scholar]
  • 50.Alshurtan KS, Aldhaifi SY, Alamrani SA. Community awareness of obstructive sleep apnea (OSA): Saudi Arabia. Sleep Breath. 2025;29:271. doi: 10.1007/s11325-025-03436-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Preventive Medicine are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES